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Reply to Elson et al.
To the Editor:
We recently reported an association study of common
mtDNA variation with risk of type 2 diabetes and metabolic
traits.1 We tested a simple model with few assumptions: that
each common DNA sequence variant might, irrespective of
its place in the mtDNA phylogeny, be associated with dis-
ease. Although Elson et al.2 agree that our “approach will
detect a robust disease association,” they have three con-
cerns: (i) that the catalogue of common variation is not
representative of European mtDNAs, (ii) that our tag SNPs
do not adequately capture mtDNA haplogroups, and (iii)
that we failed to consider epistasis. We believe these views
to be misinterpretations of our article, as well as a reflection
of a difference in philosophy on limiting associationstudies
on the basis of prior assumptions.
We developed a catalogue of common mtDNA variation
on the basis of publicly available mtDNA sequences. Per-
haps we were insufficiently precise in the text, as Elson et
al. misinterpret which samples were used. In the European
alignment, we studied 928 mtDNAs of only European or-
igin: 429 from MitoKor, 240 from the Armed Forces Insti-
tute of Pathology, 192 from Finland, and 67 from smaller
studies. (Although we used 536 MitoKor sequences for
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worldwide alignment, only 429 were included in subse-
quent analyses.)
Elson et al. criticize our inclusion of m.13105, which
they describe as “most often associated with African lin-
eages.”2 Although it is true that m.13105 is more common
in African samples, it is present at a frequency of 1.2% in
the 6,000 European samples we studied and at 3% in Hap-
Map CEU samples.3 We are perplexed as to why Elson et
al. write that this variant “should not have been used in
the analysis,”2 because it is in fact present in our samples
and could, in principle, influence traits. We do agree that
our catalogue is only as representative as the public data-
base used to create it. We note that association testing
performed using tags from 928 complete sequences is dra-
matically more complete than current standards.
Second, Elson et al. assert that our tag SNP and testing
strategy captures only a small fraction of European mtDNA
phylogeny.2,4 As shown in table 4 of our article,1 the com-
mon variants identified, as well as nine canonical Euro-
pean haplogroups, are well predicted by the tag SNPs and
specified haplotype tests. Perhaps Elson et al. do not con-
sider the specified haplotype tests that we performed, as,
in their example (shown in red in their fig. 1), although
no single SNP captures m.5046 of haplogroup W, a spec-
ified haplotype test (that we did perform) does. We do not
understand why Elson et al. argue that our strategy might
lead to “spurious associations,”2 nor do Elson et al. provide
an explanation of this claim.
Third, we agree that interaction among variants may
alter risk, which is why we performed pairwise tests involv-
ing all SNPs with nominal in the initial screen.1(p57)P ! .1
Marchini et al. showed this approach to be well powered.5,6
Finally, Elson et al. argue that limiting association tests
to the classical phylogeny and variants with “direct func-
tional consequences” will “increase the power of the
study.”2 We agree—under the model in which their assump-
tions are correct. Of course, under the model in which some
causal variants are not restricted to a classical haplogroup
or might not yet be suspected as contributing to disease,
power will decrease under the advocated approach.
RICHA SAXENA, PAUL I. W. DE BAKKER, LEIF C. GROOP,
MARK J. DALY, AND DAVID ALTSHULER
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Genetic Association Analysis of RHOB and
TXNDC3 in Osteoarthritis
To the Editor:
In the May 2006 issue of The American Journal of Human
Genetics, Mahr et al.1 reported an association with osteo-
arthritis (OA [MIM 165720]) for a SNP (rs49846015) lo-
cated immediately 5′ of the coding region of RHOB (on
chromosome 2p24.1 [MIM 165370]) and for a SNP
(rs4720262) located immediately 5′ of the coding region
of TXNDC3 (on chromosome 7p14.1 [MIM 607421]).
RHOB codes for a GTP-binding protein whereas TXNDC3
codes for a thioredoxin protein. The association study by
Mahr et al. was performed with 171 patients with OA (74%
females) who had undergone joint-replacement surgery
(68% knee and 32% hip) and with 182 healthy control
subjects (66% females), all of European white ethnicity.
Possession of a copy of the G allele of rs49846015 was an
OA risk factor ( ), as was possession of the T allelePp .0007
of rs4720262 ( ).Pp .0007
To assess the robustness of these associations, we have
genotyped the SNPs in our collection of 11,500 case pa-
tients with OA (mean age 65 years; age range 56–85 years)
and 1700 age-matched control subjects (mean age 69
years; age range 55–89 years). As in the study by Mahr et
al.,1 our case patients were ascertained by joint-replace-
ment surgery (hip, knee, or hip and knee) due to severe
end-stage OA. Our control subjects had no signs or symp-
toms of arthritis or joint disease (pain, swelling, tender-
ness, or restriction of movement). All case patients and
control subjects were individuals from the United King-
dom who are of white European ethnicity. Further details
about the ascertainment of our case patients and control
subjects have been published elsewhere.2 Ethical approval
for our study was obtained from the appropriate ethics
